GEMCITABINE MEDAC 1500 MG Israel - engelsk - Ministry of Health

gemcitabine medac 1500 mg

tzamal bio-pharma ltd - gemcitabine as hydrochloride - powder for solution for infusion - gemcitabine as hydrochloride 1500 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locallyadvanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreaticcancer.gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage.breast cancer:gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locallyrecurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy.prior chemotherapy should have included an anthracycline unless clinically contraindicated.ovarian cancer:gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelialovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Gemcitabine 1000 mg PCH, poeder voor oplossing voor infusie Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

gemcitabine 1000 mg pch, poeder voor oplossing voor infusie

pharmachemie b.v. swensweg 5 2031 ga haarlem - gemcitabinehydrochloride 1140 mg/flacon samenstelling overeenkomend met ; gemcitabine 1000 mg/flacon - poeder voor oplossing voor infusie - mannitol (d-) (e 421) ; natriumacetaat 3-water (e 262) ; natriumhydroxide (e 524) ; stikstof (head space) (e 941), - gemcitabine

Gemcitabine 1000 mg Pharmachemie B.V., poeder voor oplossing voor infusie Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

gemcitabine 1000 mg pharmachemie b.v., poeder voor oplossing voor infusie

pharmachemie b.v. swensweg 5 2031 ga haarlem - gemcitabinehydrochloride 1140 mg/flacon samenstelling overeenkomend met ; gemcitabine 1000 mg/flacon - poeder voor oplossing voor infusie - mannitol (d-) (e 421) ; natriumacetaat 3-water (e 262) ; natriumhydroxide (e 524) ; stikstof (head space) (e 941), - gemcitabine

Gemcitabine 200 mg PCH, poeder voor oplossing voor infusie Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

gemcitabine 200 mg pch, poeder voor oplossing voor infusie

pharmachemie b.v. swensweg 5 2031 ga haarlem - gemcitabinehydrochloride 228 mg/flacon samenstelling overeenkomend met ; gemcitabine 200 mg/flacon - poeder voor oplossing voor infusie - mannitol (d-) (e 421) ; natriumacetaat 3-water (e 262) ; natriumhydroxide (e 524) ; stikstof (head space) (e 941), - gemcitabine

Gemcitabine 200 mg Pharmachemie B.V., poeder voor oplossing voor infusie Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

gemcitabine 200 mg pharmachemie b.v., poeder voor oplossing voor infusie

pharmachemie b.v. swensweg 5 2031 ga haarlem - gemcitabinehydrochloride 228 mg/flacon samenstelling overeenkomend met ; gemcitabine 200 mg/flacon - poeder voor oplossing voor infusie - mannitol (d-) (e 421) ; natriumacetaat 3-water (e 262) ; natriumhydroxide (e 524) ; stikstof (head space) (e 941), - gemcitabine

GEMCITABINE ACTAVIS 200 gemcitabine 200 mg (as hydrochloride) powder for injection vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

gemcitabine actavis 200 gemcitabine 200 mg (as hydrochloride) powder for injection vial

medis pharma pty ltd - gemcitabine hydrochloride, quantity: 228 mg (equivalent: gemcitabine, qty 200 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; sodium acetate trihydrate - treatment of patients with locally advanced or metastatic non-small cell lung cancer. treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. treatment of patients with fu refractory pancreatic cancer. treatment of patients with bladder cancer, alone or in combination with cisplatin. treatment, in combination with paclitaxel, of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment, in combination with carboplatin, of patients with recurrent epithelial ovarian carcinoma, who have relapsed >six months following platinum based therapy.

DBL GEMCITABINE FOR INJECTION gemcitabine (as hydrochloride) 2 g powder for injection vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

dbl gemcitabine for injection gemcitabine (as hydrochloride) 2 g powder for injection vial

pfizer australia pty ltd - gemcitabine hydrochloride -

DBL GEMCITABINE FOR INJECTION gemcitabine (as hydrochloride) 1 g powder for injection vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

dbl gemcitabine for injection gemcitabine (as hydrochloride) 1 g powder for injection vial

pfizer australia pty ltd - gemcitabine hydrochloride -

DBL GEMCITABINE FOR INJECTION gemcitabine (as hydrochloride) 200 mg powder for injection vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

dbl gemcitabine for injection gemcitabine (as hydrochloride) 200 mg powder for injection vial

pfizer australia pty ltd - gemcitabine hydrochloride -

GEMCITABINE MEDAC 200 MG Israel - engelsk - Ministry of Health

gemcitabine medac 200 mg

tzamal bio-pharma ltd - gemcitabine as hydrochloride - powder for solution for infusion - gemcitabine as hydrochloride 200 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.